Blinatumomab Trimer Formation
Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…
Certara2024 年 9 月 16 日
Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities
Panelists: Adekemi Taylor, PhD, VP, Quantitive Science Services at CertaraJoab Williamson, Director of Clinical Operations,…
Certara2024 年 9 月 16 日
A tutorial on physiologically based pharmacokinetic approaches in lactation research
The tutorial by Amita Pansari, Xian Pan, Lisa M. Almond, and Karen Rowland-Yeo examines the…
Certara2024 年 9 月 16 日
All You Need to Know About Non-CRF Data in Clinical Trials
We look at the role of non-CRF data in clinical trials, and best practices for…
Certara2024 年 9 月 16 日
The SDTM Mapping Process Simplified
SDTM mapping can be one of the most challenging programming problems in a clinical trial…
Certara2024 年 9 月 16 日
What Are SDTM Supplemental Qualifiers?
We touched on the SDTM supplemental qualifier in the SDTM mapping process simplified. In this…
Certara2024 年 9 月 16 日
From Development to Patient Impact: Biohaven’s Nurtec™ Success Story
To learn more about Biohaven's success story, read our case study. 阅读案例研究
Certara2024 年 9 月 13 日
4 Ways That Mechanistic Modeling Accelerates Bispecific (and Multispecific) Antibody Drug Development
With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…
Certara2024 年 9 月 12 日
